Is It PMOS, or Perimenopause? Telling Them Apart in Your Late 30s and 40s

You've had PCOS — now PMOS, after the Lancet consensus paper in May 2026 — since your twenties. You know your version of irregular. Then sometime in your late thirties or forties the pattern changes again: cycles stretch out, or bunch up, the hot nights start, the mood shifts. And the question lands. Is this the PMOS you've always had, finally getting worse? Or is it perimenopause arriving on top of it?

It's one of the harder calls in women's health, because both conditions produce the same headline symptom — an irregular cycle — and both can be true at once. Here's how clinicians actually tell them apart, and what to ask for.

Two conditions, one symptom

PMOS and perimenopause are almost opposites under the hood, and they meet at the same surface complaint. PMOS is a metabolic and endocrine condition driven by insulin resistance and higher androgens — the cycle is irregular because ovulation is unreliable. Perimenopause is the ovary winding down: the follicle supply is running low, and the hormonal feedback that times a cycle starts to fray.

Same missed and unpredictable periods. Two completely different engines. And because the symptom lists overlap — irregular cycles, weight that won't shift, low mood, poor sleep, thinning hair — symptom-matching alone won't settle it. The blood test pattern will get you most of the way.

The hormone patterns point in opposite directions

This is the useful part: the two conditions move the key hormones in different directions.

In PMOS, AMH (anti-Müllerian hormone) tends to run high — it reflects a large pool of small follicles — and androgens are elevated, often with a raised LH-to-FSH ratio. AMH was formally added as a diagnostic marker in the 2023 International Evidence-Based Guideline for PCOS, precisely because it tracks the ovarian picture.

In perimenopause, the movement is the reverse: FSH rises and estradiol drifts down as the ovary's follicle reserve falls, and AMH declines with age. So a midlife woman whose AMH has dropped toward the floor and whose FSH is climbing is telling a perimenopausal story, not a PMOS one.

One honest caveat we won't gloss over, because the popular guides usually do: a single FSH reading cannot confirm or rule out perimenopause. FSH swings enormously from cycle to cycle in the transition — that's why the 2012 STRAW+10 staging consensus, the reference framework for reproductive aging, treats perimenopause as a clinical picture built from cycle history and symptoms, not a number on one blood test. Estradiol can even spike up in early perimenopause before it falls. So one off FSH doesn't close the case either way; it's a clue, not a verdict.

Your history is the cheapest clue

Before any blood test, the timeline does a lot of the work — and it's free.

PMOS is lifelong. The ovulatory dysfunction shows up early — irregular cycles from the teens or twenties, often with acne or unwanted hair growth that started young. If your periods have been unpredictable since you were nineteen, the smart first assumption for a baseline of irregularity is PMOS.

Perimenopause doesn't arrive until midlife — typically within roughly a ten-year window before menopause, so late thirties at the earliest, more often forties. So the question isn't really "PMOS or perimenopause" in isolation. It's: has something changed recently, on top of a pattern I already knew? A new flavour of irregular — new hot flushes, new sleep disruption, cycles behaving in a way they never did before — in a woman who's always had PMOS is the classic signature of perimenopause layering on.

When PMOS quietens — and when it's both

Here's the counterintuitive bit. For many women, PMOS doesn't get louder approaching menopause — it gets a little quieter. Androgen levels gradually decline from the third decade onward, and cycles in PMOS often become more regular as the years pass and the rest of the ovarian field catches up to the still-elevated follicle count. So a woman bracing for her PMOS to worsen with age is sometimes surprised it eases.

Which is exactly why a fresh burst of irregularity in your forties deserves a second look rather than a shrug. If your cycles had settled and then went haywire again, that's less likely to be your old PMOS and more likely to be perimenopause entering the room.

But the part that matters most for the long game: the metabolic side of PMOS does not retire at menopause. The insulin resistance, the raised risk of type 2 diabetes and cardiovascular disease, the whole-body picture — those persist, and some risks climb after menopause. So even as the period question resolves itself, the reason we treat PMOS as a metabolic condition stays just as relevant at 50 as at 30.

What to ask for

If you're in this window and unsure which story you're in, a single targeted panel sorts most of it:

• AMH — high points toward PMOS, low-for-age toward perimenopause.
• Androgens and SHBG — free testosterone (FAI) and SHBG; still-elevated androgens favour PMOS. (Asian women more often carry a low-SHBG pattern, which raises active testosterone at "normal" totals — see our lean PMOS piece.)
• FSH with estradiol — read together, and read with the caveat above: one value doesn't settle it, so timing and repetition matter.
• The metabolic markers your panel tends to skip — fasting insulin, HOMA-IR, an HbA1c. Whichever story it is, the metabolic risk is the part that follows you, so don't let the hormone question crowd it out. Our labs a PMOS workup tends to skip covers why these get left off.

If it turns out to be both — and in your forties it often is — that's not a contradiction. It just means two things are true, and the plan addresses both: the perimenopause symptoms on their own terms, and the metabolic thread that was always the real centre of PMOS. Our post-pill amenorrhea piece walks through a sister version of this same "is it PMOS, or something that looks like it?" question.

Where to start

If your cycle changed and you're not sure which story it belongs to, our free 5-minute assessment maps the pattern behind your symptoms and shows you a result without asking for anything in return — a structured place to start before you book the bloodwork.

Citations

• Teede HJ, et al. Renaming polycystic ovary syndrome: a Lancet consensus. The Lancet, 2026 (PCOS → PMOS).
• International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, 2023 (AMH incorporated as a diagnostic marker; guidance across the lifespan).
• Harlow SD, et al. Executive summary of the Stages of Reproductive Aging Workshop +10 (STRAW+10). Menopause / J Clin Endocrinol Metab, 2012 — staging of reproductive aging; FSH unreliable as a single-value test.